China's Outsource Sales Model Takes A Big Step: SciClone Takes Out NovaMed

SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18